Sign in Create account
Sign in and upgrade to a paid plan to export price history as CSV.

Solara Active Pharma Sciences Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: SOLARA BSE: 541540
₹725.40
▼ -24.45 (-3.26%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
33/100
Weak
Valuation
64/100
Fairly Valued
Momentum
53/100
Neutral

QVM read Mixed signals Quality Weak, Valuation Fairly Valued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹3,500 Cr
PE (TTM)
Data unavailable.
Price to Book
2.8
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
15.26%
FII + DII, latest filed period
Piotroski Score
5
Relative return vs Nifty50, qtr %
32.0
Relative return vs Sector, qtr %
28.1
Free Cash Flow
₹100 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
49.19%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-157.78%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
9.89%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
61.35%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
19.57%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
0.96
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.53
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
0.99
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
4.45%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
9.75%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
6.27%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
-0.32%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
6.07%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
-0.59%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

1 of 8 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 5)
  • No Debt to equity is below 0.5 (0.53)
  • No Return on equity is 15% or more (-0.6%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 4 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • No Promoter holding rose or was unchanged in the latest quarter
  • No Promoter pledge is 5% of their holding or less and not rising (37.1% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

3 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

1 of 5 met
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-3.3%
Low 720.0000 · High 759.0000
1W return
0.3%
Low 715.0000 · High 767.9000
1M return
14.7%
Low 619.0000 · High 774.0000
52W return
19.8%
Low 422.0000 · High 774.0000
Lifetime High ₹1810.9500 (May 19, 2021)
Lifetime Low ₹136.6000 (July 12, 2018)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish4
Bearish2
5D
735.0
10D
730.5
20D
707.5
50D
648.8
100D
604.4
200D
546.8

Delivery and volume

Day avg. delivery
39.3%
Week avg. delivery
36.4%
Month avg. delivery
36.8%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

734.80
Pivot
First resistance749.60
Second resistance773.80
Third resistance788.60
First support710.60
Second support695.80
Third support671.60
Day RSI59.2
Day MFI61.3
Day MACD34.13
Day MACD signal38.66

Beta

1M0.80
3M0.86
1Y0.76
3Y1.02

Price change analysis

↑ 14.7%
Over 1 Month
LowHigh
619.00774.00
↑ 28.1%
Over 3 Months
LowHigh
471.55774.00
↑ 58.0%
Over 6 Months
LowHigh
442.00774.00
↑ 19.8%
Over 1 Year
LowHigh
422.00774.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹382 Cr
Net profit (June 30, 2026)
₹17 Cr
Basic EPS (June 30, 2026)
₹3.6700

Ranks #68 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter41.93%
  • Mutual funds0.95%
  • FII/FPI11.52%
  • Other DII2.79%
  • Public42.81%

Largest holders

NameCategoryShares %Shares
DEVICAM CAPITAL LLPPromoter15.4700%7463560
PRONOMZ VENTURES LLPPromoter9.7100%4685529
AUTHUM INVESTMENT AND INFRASTRUCTURE LIMITEDPublic3.7800%1824592
SPIRACCA VENTURES LLP .Public3.5400%1708503
SRJR ENTERPRISE LLPPromoter3.5200%1700100

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings decreased from 42.00% to 41.93% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 11.33% to 11.52% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 1.16% to 0.95% in Jun 2026 qtr

All shareholding details →

Insider trading, SAST & pledges

All 308 insider trades, 28 SAST, 132 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
1 Jul 2025 Poorvank Purohit Other Sell 0 ₹0
1 Jul 2025 Poorvank Purohit Other Sell 0 ₹0
27 Jun 2025 Vishal Mathur Other Buy 0 ₹0
19 Jun 2025 Pronomz Ventures LLP Promoter Buy 0 ₹0
9 Jun 2025 Sandeep Shashikantha Rao Director Buy 0 ₹0
14 Mar 2025 Kausalya Santhanam Director Buy 0 ₹0
6 Mar 2025 Pronomz Ventures LLP Promoter Buy 0 ₹0
4 Mar 2025 Pronomz Ventures LLP Promoter Buy 0 ₹0
28 Feb 2025 Pronomz Ventures LLP Promoter Buy 0 ₹0
14 Feb 2025 Pronomz Ventures LLP Promoter Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 96 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
20 Aug 2026 JUNOMONETA FINSOL PRIVATE LIMITED Bulk Buy 283,420 626.1900 NSE
20 Aug 2026 JUNOMONETA FINSOL PRIVATE LIMITED Bulk Sell 282,513 626.8200 NSE
16 Jun 2025 SPIRACCA VENTURES LLP Block Sell 2,000,000 495.0000 NSE
16 Jun 2025 PRONOMZ VENTURES LLP Block Buy 2,000,000 495.0000 NSE
16 Jun 2025 SPIRACCA VENTURES LLP Bulk Sell 2,000,000 495.0000 NSE
16 Jun 2025 PRONOMZ VENTURES LLP Bulk Buy 2,000,000 495.0000 NSE
24 Feb 2025 BHATIA SURESH Block Sell 204,527 490.0000 BSE
24 Feb 2025 AARTI BHATIA Block Buy 204,527 490.0000 BSE
24 Feb 2025 AARTI BHATIA Bulk Buy 204,527 490.0000 BSE
24 Feb 2025 BHATIA SURESH Bulk Sell 204,527 490.0000 BSE

All bulk and block deals →

Dividends

Full dividend history →
Ex-dateSubjectPer share (₹)Record date
18 Aug 2021 Annual General Meeting/Dividend - Rs 3 Per Share 3.0000 20 Aug 2021
19 Nov 2020 Interim Dividend - Rs 4 Per Share 4.0000 20 Nov 2020
28 Jul 2020 Annual General Meeting/Dividend - Rs 2 Per Share 2.0000 —
6 Aug 2019 Annual General Meeting/Dividend - Rs 5 Per Share 5.0000 —

Corporate Actions

Full history (9 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
17 Sep 2024OTHERAnnual General Meeting
15 May 2024RIGHTSRights 1:3 @ Premium Rs 365/-
8 Sep 2023OTHERAnnual General Meeting
12 Aug 2022OTHERAnnual General Meeting
18 Sep 2018OTHER Annual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
23 Jul 2026 Financial Results Yes
15 May 2026 Financial Results Yes
6 Feb 2026 Financial Results Yes
5 Nov 2025 Financial Results Yes
25 Jul 2025 Financial Results Yes

Corporate Announcements

All 660 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
26 Sep 2026 General Updates Intimation to furnish valid PAN, KYC details and Nomination by shareholders holding physical shares
25 Sep 2026 Trading Window Solara Active Pharma Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
25 Sep 2026 Insider Trading / SAST Solara Active Pharma Sciences Ltd - 541540 - Closure of Trading Window
22 Sep 2026 Shareholders meeting SOLARA: Solara Active Pharma Sciences Limited has informed the exchange regarding the Voting Results and the Scrutinizer's report of the Ninth Annual General Meeting
18 Sep 2026 AGM/EGM Solara Active Pharma Sciences Ltd - 541540 - Shareholder Meeting / Postal Ballot-Outcome of AGM
18 Sep 2026 Shareholders meeting Solara Active Pharma Sciences Limited has informed the Exchange regarding Proceedings of Ninth Annual General Meeting held on September 18, 2026
28 Aug 2026 Updates SOLARA: Solara Active Pharma Sciences Limited has informed the Exchange regarding Intimation in connection with the receipt of Rectification Order.
26 Aug 2026 Copy of Newspaper Publication SOLARA: Solara Active Pharma Sciences Limited has informed the Exchange about Copy of Newspaper Publication regarding the completion of dispatch of 9th AGM Notice and Annual report
25 Aug 2026 General Updates Solara Active Pharma Sciences Limited has informed the Exchange about Business Responsibility and Sustainability Report for the financial year 2025-26.
25 Aug 2026 Shareholders meeting Solara Active Pharma Sciences Limited has informed the exchange about the dispatch of Notice of Ninth Annual General Meeting ("AGM") of the Company scheduled to be held on Friday, September 18, 2026.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong revenue growth YoY (19.6%)

Weaknesses

  • Low Return on Equity (-0.6%)
  • Thin net profit margin (4.5%)
  • Tight liquidity (Current Ratio 0.96)

Opportunities

Data unavailable.

Threats

  • Weak interest coverage (1.0x) -- limited cushion against rising rates

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Solara Active Pharma Sciences Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.